NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
NovoCure Limited NVCR
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$655.4M
▲ 8.3% vs FY2024
EPS · FY25
$-1.22
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-38.9%
Net margin · FY25
-20.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 655.4M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
USD -1.22
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-38.9%
Return on equity, FY2025
ROE
Operating margin-23.5%
Net margin-20.8%
Return on assets-13.3%
Each USD of equity lost 39 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.8%
+5.8%
+34.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+9.9%
Change, 10 years+34.3%
The share count grew 10% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 804.3M
total assets, end of FY2025
Total assetsUSD 804.3M
EquityUSD 340.5M
CashUSD 93.5M
Gross debtUSD 195.0M
Net debtUSD 101.5M
Current ratio2.90×
Net debt stands at 30% of equity.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.7
0.6
0.5
0.5
0.5
0.5
0.4
0.2
0.2
0.1
0.0
0.0
0.0
Operating income $B
−0.2
−0.2
−0.2
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.2
−0.2
−0.1
−0.0
0.0
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.2
−0.2
−0.1
−0.1
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−1.22
−1.56
−1.95
−0.88
−0.56
0.18
−0.07
−0.69
−0.70
−1.54
−3.67
−6.46
−6.73
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
−0
−0
−0
·
·
ROE %
−38.9
−46.7
−51.5
−21.7
−13.2
5.7
−4.4
−56.3
−48.2
−67.1
−64.0
−59.8
−45.0
Shares out B
0.11
0.11
0.11
0.11
0.10
0.10
0.10
0.09
0.09
0.09
0.08
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 50
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed